Last reviewed · How we verify
ASP4070
ASP4070 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.
ASP4070 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation. Used for Complement-mediated inflammatory diseases (Phase 2 development).
At a glance
| Generic name | ASP4070 |
|---|---|
| Sponsor | Astellas Pharma Inc |
| Drug class | C5a receptor antagonist |
| Target | C5a receptor (C5aR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
ASP4070 blocks the C5a receptor on immune cells, preventing the recruitment and activation of neutrophils and other inflammatory cells downstream of complement cascade activation. By inhibiting this key inflammatory pathway, the drug aims to reduce tissue damage and inflammation in complement-driven diseases.
Approved indications
- Complement-mediated inflammatory diseases (Phase 2 development)
Common side effects
Key clinical trials
- A Dose-finding Study of ASP4070 (PHASE2)
- A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP4070 CI brief — competitive landscape report
- ASP4070 updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI